Annual report
8086.TEDINET S100R5KJ
Period2022-04-01 → 2023-03-31
Filed2023-06-28
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 154
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥545.2bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales |
| Revenue | ¥494.8bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales |
| Revenue | ¥455.6bn | 2020-04-01 → 2021-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥442.5bn | 2019-04-01 → 2020-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥426.4bn | 2018-04-01 → 2019-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥17.7bn | 2022-04-01 → 2023-03-31 | Cons. | Operating income |
| Operating income | ¥23.9bn | 2021-04-01 → 2022-03-31 | Cons. | Operating income |
| Ordinary income | ¥15.3bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥27.6bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥26.3bn | 2020-04-01 → 2021-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥23.4bn | 2019-04-01 → 2020-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥22.4bn | 2018-04-01 → 2019-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥16.8bn | 2022-04-01 → 2023-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥23.2bn | 2021-04-01 → 2022-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥4.6bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥13.5bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥14.2bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥12.3bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥12.1bn | 2018-04-01 → 2019-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥5.9bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss |
| Net income | ¥15.1bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss |
| Total assets | ¥1.03T | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥930.3bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥854.4bn | at 2021-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥831.9bn | at 2020-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥845.8bn | at 2019-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥785.2bn | at 2023-03-31 | Cons. | Liabilities |
| Total liabilities | ¥730.5bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥242.2bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥199.9bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥174.1bn | at 2021-03-31d | Cons. | Net assets |
| Net assets / equity | ¥161.2bn | at 2020-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥171.8bn | at 2019-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥89.7bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥95.3bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥84.7bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥90.1bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥85.8bn | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥90.2bn | at 2020-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥120.3bn | at 2019-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥10.4bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥68.2bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥66.1bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥37.2bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥41.4bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥71.7bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥78.4bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥45.1bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥58.3bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥64.7bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | ¥43.1bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥10.3bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥22.1bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥4.6bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥12.6bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥28.05 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥82.5 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥87.12 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-75.3 | 2019-04-01 → 2020-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥73.68 | 2018-04-01 → 2019-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥24.85 | 2022-04-01 → 2023-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥77.42 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥66.75 | 2018-04-01 → 2019-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥1,265 | at 2023-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,135.76 | at 2022-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥987.3 | at 2021-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥912.24 | at 2020-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥990.14 | at 2019-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 20.1% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 19.9% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 18.8% | at 2021-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 17.9% | at 2020-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 19.1% | at 2019-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 2.3% | 2022-04-01 → 2023-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 7.8% | 2021-04-01 → 2022-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 9.2% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | -7.9% | 2019-04-01 → 2020-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 7.3% | 2018-04-01 → 2019-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 38,770 | at 2023-03-31 | Cons. | Number of employees |
| Employees | 36,259 | at 2022-03-31 | Cons. | Number of employees |
| Employees | 35,251 | at 2021-03-31d | Cons. | Number of employees |
| Employees | 32,786 | at 2020-03-31d | Cons. | Number of employees |
| Employees | 29,325 | at 2019-03-31d | Cons. | Number of employees |
| Revenue | ¥349.7bn | 2022-04-01 → 2023-03-31 | Standalone | Net sales |
| Revenue | ¥331.2bn | 2021-04-01 → 2022-03-31 | Standalone | Net sales |
| Revenue | ¥334.9bn | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥340.8bn | 2019-04-01 → 2020-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥310.6bn | 2018-04-01 → 2019-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥3.3bn | 2022-04-01 → 2023-03-31 | Standalone | Operating income |
| Operating income | ¥11.6bn | 2021-04-01 → 2022-03-31 | Standalone | Operating income |
| Ordinary income | ¥8.7bn | 2022-04-01 → 2023-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥17.5bn | 2021-04-01 → 2022-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥16.5bn | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥16.1bn | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥17.4bn | 2018-04-01 → 2019-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥11.6bn | 2022-04-01 → 2023-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥14.7bn | 2021-04-01 → 2022-03-31 | Standalone | Income before income taxes |
| Net income | ¥8.7bn | 2022-04-01 → 2023-03-31 | Standalone | Profit loss |
| Net income | ¥10.7bn | 2021-04-01 → 2022-03-31 | Standalone | Profit loss |
| Net income | ¥9.7bn | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | −¥16.4bn | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥12.2bn | 2018-04-01 → 2019-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥764.9bn | at 2023-03-31 | Standalone | Assets |
| Total assets | ¥727.0bn | at 2022-03-31 | Standalone | Assets |
| Total assets | ¥695.1bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥666.1bn | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥654.7bn | at 2019-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥583.3bn | at 2023-03-31 | Standalone | Liabilities |
| Total liabilities | ¥547.2bn | at 2022-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥181.6bn | at 2023-03-31 | Standalone | Net assets |
| Net assets / equity | ¥179.7bn | at 2022-03-31 | Standalone | Net assets |
| Net assets / equity | ¥173.7bn | at 2021-03-31d | Standalone | Net assets |
| Net assets / equity | ¥157.7bn | at 2020-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥171.0bn | at 2019-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥7.6bn | at 2023-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥7.1bn | at 2022-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥53.47 | 2022-04-01 → 2023-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥65.87 | 2021-04-01 → 2022-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥59.72 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-100.66 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥74.25 | 2018-04-01 → 2019-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥47.38 | 2022-04-01 → 2023-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥61.82 | 2021-04-01 → 2022-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥67.27 | 2018-04-01 → 2019-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥22 | 2022-04-01 → 2023-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥27 | 2021-04-01 → 2022-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥28 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥13.5 | 2019-04-01 → 2020-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥28 | 2018-04-01 → 2019-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥1,113.64 | at 2023-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,102.07 | at 2022-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,065.15 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥966.84 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,048.54 | at 2019-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 23.7% | at 2023-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 24.7% | at 2022-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 25.0% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 23.7% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 26.1% | at 2019-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 4.8% | 2022-04-01 → 2023-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.1% | 2021-04-01 → 2022-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 5.9% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | -10.0% | 2019-04-01 → 2020-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 7.1% | 2018-04-01 → 2019-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 171,459,000 | at 2023-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 171,459,000 | at 2022-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 171,459,000 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 171,459,000 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 171,459,000 | at 2019-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 4,390 | at 2023-03-31 | Standalone | Number of employees |
| Employees | 4,252 | at 2022-03-31 | Standalone | Number of employees |
| Employees | 4,150 | at 2021-03-31d | Standalone | Number of employees |
| Employees | 4,060 | at 2020-03-31d | Standalone | Number of employees |
| Employees | 3,893 | at 2019-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 103
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | capex | 2022-04-01 → 2023-03-31 | ¥365m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | depreciation | 2022-04-01 → 2023-03-31 | ¥339m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2023-03-31 | 118 pure |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-04-01 → 2023-03-31 | ¥4.4bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-04-01 → 2023-03-31 | ¥752m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥3.7bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2023-03-31 | ¥201.7bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-04-01 → 2023-03-31 | ¥257m |
| Reconciling Itemsreconciling | capex | 2022-04-01 → 2023-03-31 | ¥14.0bn |
| Reconciling Itemsreconciling | depreciation | 2022-04-01 → 2023-03-31 | ¥4.6bn |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2023-03-31 | −¥38.3bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2023-03-31 | −¥38.3bn |
| Reconciling Itemsreconciling | segment assets | at 2023-03-31 | −¥111.7bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2023-03-31 | −¥29.5bn |
| Medical Treatment Relatedreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥49.1bn |
| Medical Treatment Relatedreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥22.5bn |
| Medical Treatment Relatedreportable segment | employees | at 2023-03-31 | 27220 pure |
| Medical Treatment Relatedreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥426.1bn |
| Medical Treatment Relatedreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥420.0bn |
| Medical Treatment Relatedreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥6.1bn |
| Medical Treatment Relatedreportable segment | segment assets | at 2023-03-31 | ¥618.6bn |
| Medical Treatment Relatedreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥38.6bn |
| Medicine Relatedreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥23.5bn |
| Medicine Relatedreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥13.4bn |
| Medicine Relatedreportable segment | employees | at 2023-03-31 | 7331 pure |
| Medicine Relatedreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥95.2bn |
| Medicine Relatedreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥72.7bn |
| Medicine Relatedreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥22.5bn |
| Medicine Relatedreportable segment | segment assets | at 2023-03-31 | ¥221.6bn |
| Medicine Relatedreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥5.6bn |
| Pharma Packagingreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥15.7bn |
| Pharma Packagingreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥5.5bn |
| Pharma Packagingreportable segment | employees | at 2023-03-31 | 3303 pure |
| Pharma Packagingreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥57.7bn |
| Pharma Packagingreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥51.8bn |
| Pharma Packagingreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥6.0bn |
| Pharma Packagingreportable segment | segment assets | at 2023-03-31 | ¥97.2bn |
| Pharma Packagingreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥2.7bn |
| —segment total | capex | 2022-04-01 → 2023-03-31 | ¥88.2bn |
| —segment total | depreciation | 2022-04-01 → 2023-03-31 | ¥41.3bn |
| —segment total | revenue | 2022-04-01 → 2023-03-31 | ¥579.0bn |
| —segment total | revenue external | 2022-04-01 → 2023-03-31 | ¥544.4bn |
| —segment total | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥34.6bn |
| —segment total | segment assets | at 2023-03-31 | ¥937.4bn |
| —segment total | segment profit | 2022-04-01 → 2023-03-31 | ¥47.0bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2022-04-01 → 2023-03-31 | ¥88.6bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2022-04-01 → 2023-03-31 | ¥41.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2023-03-31 | ¥583.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2023-03-31 | ¥545.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥38.3bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2023-03-31 | ¥1.14T |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2023-03-31 | ¥47.2bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | capex | 2021-04-01 → 2022-03-31 | ¥281m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | depreciation | 2021-04-01 → 2022-03-31 | ¥299m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2021-04-01 → 2022-03-31 | ¥2.7bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2021-04-01 → 2022-03-31 | ¥559m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥2.1bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2022-03-31 | ¥158.4bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2021-04-01 → 2022-03-31 | ¥101m |
| Reconciling Itemsreconciling | capex | 2021-04-01 → 2022-03-31 | ¥7.0bn |
| Reconciling Itemsreconciling | depreciation | 2021-04-01 → 2022-03-31 | ¥4.7bn |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2022-03-31 | −¥35.2bn |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2022-03-31 | −¥35.2bn |
| Reconciling Itemsreconciling | segment assets | at 2022-03-31 | −¥57.0bn |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2022-03-31 | −¥28.2bn |
| Medical Treatment Relatedreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥56.8bn |
| Medical Treatment Relatedreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥20.1bn |
| Medical Treatment Relatedreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥379.8bn |
| Medical Treatment Relatedreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥373.5bn |
| Medical Treatment Relatedreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥6.4bn |
| Medical Treatment Relatedreportable segment | segment assets | at 2022-03-31 | ¥541.9bn |
| Medical Treatment Relatedreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥39.2bn |
| Medicine Relatedreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥23.4bn |
| Medicine Relatedreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥13.4bn |
| Medicine Relatedreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥95.0bn |
| Medicine Relatedreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥74.4bn |
| Medicine Relatedreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥20.6bn |
| Medicine Relatedreportable segment | segment assets | at 2022-03-31 | ¥203.7bn |
| Medicine Relatedreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥9.8bn |
| Pharma Packagingreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥9.3bn |
| Pharma Packagingreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥4.8bn |
| Pharma Packagingreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥52.5bn |
| Pharma Packagingreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥46.4bn |
| Pharma Packagingreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥6.1bn |
| Pharma Packagingreportable segment | segment assets | at 2022-03-31 | ¥83.3bn |
| Pharma Packagingreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥2.9bn |
| —segment total | capex | 2021-04-01 → 2022-03-31 | ¥89.5bn |
| —segment total | depreciation | 2021-04-01 → 2022-03-31 | ¥38.3bn |
| —segment total | revenue | 2021-04-01 → 2022-03-31 | ¥527.3bn |
| —segment total | revenue external | 2021-04-01 → 2022-03-31 | ¥494.2bn |
| —segment total | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥33.1bn |
| —segment total | segment assets | at 2022-03-31 | ¥828.9bn |
| —segment total | segment profit | 2021-04-01 → 2022-03-31 | ¥52.0bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2021-04-01 → 2022-03-31 | ¥89.8bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2021-04-01 → 2022-03-31 | ¥38.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2022-03-31 | ¥530.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2022-03-31 | ¥494.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥35.2bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2022-03-31 | ¥987.3bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2022-03-31 | ¥52.1bn |
| Medical Treatment Relatedreportable segment | employees | at 2023-03-31 | 3406 pure |
| Medicine Relatedreportable segment | employees | at 2023-03-31 | 25 pure |
| Pharma Packagingreportable segment | employees | at 2023-03-31 | 161 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 2,116
| Item | Context | Value | Unit |
|---|---|---|---|
| Number of shares held | CurrentYearInstant | 64573000 | |
| Shareholding ratio | CurrentYearInstant | 0.3945 | |
| Number of shares issued shares voting rights | CurrentYearInstant_SharesWithNoVotingRightsMember | － | |
| Number of shares issued shares voting rights | CurrentYearInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Number of shares issued shares voting rights | CurrentYearInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of voting rights issued shares voting rights | CurrentYearInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of shares issued shares voting rights | CurrentYearInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember | 7763000 | |
| Number of voting rights issued shares voting rights | CurrentYearInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 1635957 | |
| Number of shares issued shares voting rights | CurrentYearInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 163595700 | |
| Number of shares issued shares voting rights | CurrentYearInstant_OrdinarySharesSharesLessThanOneUnitMember | 100779 | |
| Number of shares issued shares voting rights | CurrentYearInstant | 171459479 | |
| Number of voting rights issued shares voting rights | CurrentYearInstant | 1635957 | |
| Number of shares held in own name treasury shares etc | CurrentYearInstant_Row1Member | 7763000 | |
| Number of shares held in others names treasury shares etc | CurrentYearInstant_Row1Member | － | |
| Total number of shares held treasury shares etc | CurrentYearInstant_Row1Member | 7763000 | |
| Shareholding ratio treasury shares etc | CurrentYearInstant_Row1Member | 0.0453 | |
| Number of shares held in own name treasury shares etc | CurrentYearInstant | 7763000 | |
| Number of shares held in others names treasury shares etc | CurrentYearInstant | － | |
| Total number of shares held treasury shares etc | CurrentYearInstant | 7763000 | |
| Shareholding ratio treasury shares etc | CurrentYearInstant | 0.0453 | |
| Total amount of dividends dividends of surplus | FilingDateInstant_Row1Member | 2209000000 | JPY |
| Dividend per share dividends of surplus | FilingDateInstant_Row1Member | 13.50 | |
| Total amount of dividends dividends of surplus | FilingDateInstant_Row2Member | 1391000000 | JPY |
| Dividend per share dividends of surplus | FilingDateInstant_Row2Member | 8.50 | |
| Number of male directors and other officers | FilingDateInstant | 18 | |
| Number of female directors and other officers | FilingDateInstant | 3 | |
| Ratio of female directors and other officers | FilingDateInstant | 0.14 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E02688-000SanoYoshihikoMember | 105007 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E02688-000YoshiokaKiyotakaMember | 10000 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E02688-000MasudaToshiakiMember | 13518 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E02688-000KobayashiKyoetsuMember | 19772 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E02688-000MinouraKimihitoMember | 27847 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E02688-000YamazakiTsuyoshiMember | 18090 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E02688-000SanoKazuhikoMember | 16527 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E02688-000NishidaKenichiMember | 5740 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E02688-000OhyamaYasushiMember | 18663 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E02688-000YogoTakehitoMember | 6134 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E02688-000NakamuraHidetoMember | 24181 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E02688-000YoshidaToyoshiMember | 15124 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E02688-000TanakaYoshikoMember | 3805 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E02688-000ShimamoriYoshikoMember | － | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E02688-000HattoriToshiakiMember | － | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E02688-000HashimotoKatsunobuMember | 282 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E02688-000KawazuHidehikoMember | 944 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E02688-000AoyamaKiyomiMember | 944 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E02688-000NomiyaTakayukiMember | 3749 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E02688-000YanagaseShigeruMember | － | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E02688-000AkikuniYoshitakaMember | － | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant | 290327 | |
| Audit fees reporting company | Prior1YearDuration | 60000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |